Archive · 19 Dec 2025
Zydus Partners with Myriad Genetics for Cancer Tests in India
Zydus Lifesciences, a company from Ahmedabad, has teamed up with Myriad Genetics from the US.
They want to bring special tests to India that can help doctors and patients understand cancer risks better.
These tests can check if someone might get cancer because of their family history or genes.
They can also help doctors decide the best treatment for patients with prostate or ovarian cancer.
This is a big step because these tests are already used in many places around the world, like North America and Europe.
Now, doctors in India can use them too to help patients fight cancer in a smarter way.
Zydus Lifesciences has partnered with Myriad Genetics to launch cancer-risk assessment tests in India.
Tests include MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris Prostate Cancer Prognostic Test.
These tests provide personalized treatment plans and risk assessments for various cancers.
The tests are already widely adopted in North America, Europe, and major global cancer centers.
Target patients include those with cancer history, family history of cancer, or known genetic mutations.
- Who
- Zydus Lifesciences Ltd and Myriad Genetics
- What
- Launch of cancer-risk assessment diagnostic tests in India
- When
- December 19, 2025
- Where
- India
- Why
- To expand access to precision diagnostic tests for cancer treatment
- Companies Involved
- Zydus Lifesciences Ltd and Myriad Genetics
- Tests Launched
- MyRisk Hereditary Cancer Test, MyChoice HRD Plus, Prolaris Prostate Cancer Prognostic Test
- Target Market
- India
- Key Benefit
- Personalized cancer treatment and risk assessment
- Relevant Patients
- Those with cancer history, family history, or known mutations